Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 13/20 | 0.80 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | MMP8 | P22894 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | COMT | P21964 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22488739 | 0.92 | FOXO1 (0.72) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL25427295 | 0.91 | FOXO1 (0.71) | FOXO1ACHEPDE10AMMP2MMP9 | |
| SCHEMBL29524272 | 0.91 | FOXO1 (0.71) | FOXO1ACHEPDE10AMMP2MMP9 | |
| SCHEMBL25427870 | 0.88 | FOXO1 (0.68) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL29524651 | 0.88 | FOXO1 (0.68) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL29524264 | 0.88 | FOXO1 (0.71) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL25431631 | 0.88 | FOXO1 (0.71) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL25428325 | 0.88 | FOXO1 (0.70) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL30754018 | 0.88 | FOXO1 (0.70) | FOXO1ACHEPDE10ANPC1RAB9A | |
| SCHEMBL25428627 | 0.87 | FOXO1 (0.69) | FOXO1ACHEPDE10ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | FOXO1 1/4885ACHE 4176/4885PDE10A 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.